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AbstrACt
Introduction This study aims to clarify the role(s) of 
endogenous sex hormones to influence health outcomes 
in men, specifically to define the associations of plasma 
testosterone with incidence of cardiovascular events, 
cancer, dementia and mortality risk, and to identify factors 
predicting testosterone concentrations. Data will be 
accrued from at least three Australian, two European and 
four North American population- based cohorts involving 
approximately 20 000 men.
Methods and analysis Eligible studies include 
prospective cohort studies with baseline testosterone 
concentrations measured using mass spectrometry and 
5 years of follow- up data on incident cardiovascular 
events, mortality, cancer diagnoses or deaths, new- 
onset dementia or decline in cognitive function recorded. 
Data for men, who were not taking androgens or drugs 
suppressing testosterone production, metabolism or 
action; and had no prior orchidectomy, are eligible. 
Systematic literature searches were conducted from 14 
June 2019 to 31 December 2019, with no date range 
set for searches. Aggregate level data will be sought 
where individual participant data (IPD) are not available. 
One- stage IPD random- effects meta- analyses will be 
performed, using linear mixed models, generalised linear 
mixed models and either stratified or frailty- augmented 
Cox regression models. Heterogeneity in estimates from 
different studies will be quantified and bias investigated 
using funnel plots. Effect size estimates will be presented 
in forest plots and non- negligible heterogeneity and bias 
investigated using subgroup or meta- regression analyses.
Ethics and dissemination Ethics approvals obtained for 
each of the participating cohorts state that participants 
have consented to have their data collected and used for 
research purposes. The Androgens In Men Study has been 
assessed as exempt from ethics review by the Human 
Ethics office at the University of Western Australia (file 
reference number RA/4/20/5014). Each of the component 
studies had obtained ethics approvals; please refer to 
respective component studies for details. Research 
findings will be disseminated to the scientific and broader 
community via the publication of four research articles, 
with each involving a separate set of IPD meta- analyses 
(articles will investigate different, distinct outcomes), 
at scientific conferences and meetings of relevant 
professional societies. Collaborating cohort studies will 
disseminate findings to study participants and local 
communities.
PrOsPErO registration number CRD42019139668.
strengths and limitations of this study
 ► The individual participant data (IPD) meta- analyses 
are likely to have higher statistical power and pro-
vide greater scope to control for important confound-
ers and risk factors than previous meta- analyses on 
this topic.
 ► Investigators from nine large prospective cohort 
studies (each with n>1000 participants) have 
agreed to collaborate with additional studies to be 
identified from systematic review.
 ► Harmonisation will be required for some variables 
(eg, physical activity, alcohol consumption) that are 
recorded differently among the component studies, 
and aggregate- level data will be sought where IPD- 
level data are not available.
 ► As this is an observational study, it will not fully 
eliminate the possibility of confounding influences 
of unadjusted effects.
 ► However, unlike a randomised controlled trial, this 
study will provide a more comprehensive character-
isation of temporal relationships between baseline 
androgen concentrations and health outcomes in 
community- dwelling adult males.
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IntrOduCtIOn
As men grow older, testosterone production and circu-
lating concentrations of testosterone decline while comor-
bidities accumulate.1–4 Older men, even those in very 
good health, have lower circulating testosterone concen-
trations compared with healthy young men.5 6 Although 
results have been inconsistent, an increasing number of 
studies have reported associations of low endogenous 
testosterone concentration with poorer health outcomes, 
especially in older men. For instance, studies that have 
used liquid chromatography tandem mass spectrometry, 
widely regarded as the reference method for the measure-
ment of total testosterone concentrations,7 have reported 
associations of lower endogenous testosterone concen-
trations with (1) cardiovascular disease and all- cause 
mortality in some cases8–15 but not others8 16–20; (2) some 
cancers but not others21 22 and (3) dementia23 24 but not 
laboratory measures of cognitive function.25 Therefore, it 
remains unclear whether testosterone is a biomarker of ill 
health or a causal factor for diseases of ageing.
Currently, testosterone treatment is recommended for 
men who have symptoms and signs of androgen deficiency 
and low testosterone concentrations, due to disease of 
the hypothalamus, pituitary or testes (organic or patho-
logical hypogonadism).26–29 Randomised controlled trials 
of testosterone treatment in men aged 65 and older with 
low- normal testosterone concentrations without organic 
hypogonadism have shown modest benefits on sexual 
function, anaemia, self- reported physical function and 
mobility and volumetric bone density, but not on some 
objective measures of cognition over 12–36 months.30–34 
The effect of testosterone on major adverse cardiovascular 
events (MACE) remains unclear.35 36 However, the selec-
tion criteria of these trials were such that the screening 
to enrolment ratio was 65:1, a highly selected population 
of older men.32 33 36 Importantly, the trials were neither 
large enough nor long enough to determine the effects 
of testosterone on MACE, development of dementia, 
bone fractures and mortality.36 Therefore, a meta- analysis 
of data from prospective cohort studies, with extended 
follow- up periods, provides opportunities for better 
understanding of the temporal profiles of the postulated 
associations between endogenous testosterone concen-
tration and incident health outcomes. Meta- analyses of 
individual participant data (IPD) are generally preferable 
to meta- analyses of aggregate data (AD) in that they typi-
cally have higher statistical power and provide scope to 
control for important confounders and risk factors.37 38 
Furthermore, one- stage IPD meta- analyses are preferable 
to two- stage approaches because the former uses an exact 
likelihood to directly model the distribution of IPD, offers 
the convenience of using a standard set of diagnostic 
tools to assess model fit and can arguably provide greater 
flexibility, in terms of options for statistical modelling.39 40
The Androgens In Men Study (AIMS), an international 
collaboration of prospective cohort studies, will examine 
the associations of sex hormones (comprising testos-
terone and dihydrotestosterone as the major androgens, 
and oestradiol as the major oestrogen, in the circulation) 
with health outcomes that are major sources of morbidity 
and mortality in middle- aged and older men. The group 
will perform a series of IPD meta- analyses to clarify the 
influence of sex hormone exposures on major health 
outcomes, including heart attack, stroke and cardiovas-
cular deaths, cancer, new- onset dementia and all- cause 
mortality, as well as provide information on social, demo-
graphic and behavioural factors that are associated with 
endogenous testosterone concentrations. This work 
will characterise robustly the associations of several sex 
hormones with health outcomes in men in general over 
and above the study- specific estimates, and thus clarify the 
role of androgens as biomarkers for, or causal contribu-
tors to, men’s health. The work outlined in this document 
will be conducted from 1 February 2019 to 30 November 
2020.
Objectives
The AIMS will establish an international collaboration of 
existing cohort studies to clarify the relation of endog-
enous sex hormones with major health outcomes in 
men. ‘Population, exposure, outcomes’ characteristics 
include adult men in the general community; an expo-
sure of endogenous circulating sex hormone concen-
tration, primarily testosterone, as the principal male sex 
hormone or androgen; and a prospective cohort study 
type, with incident health outcomes including incidence 
of cardiovascular disease events, mortality, cancers and 
dementia. The specific objectives of the AIMS are to 
investigate associations between variables representing 
social, demographic and behavioural factors with the 
measured concentration of testosterone in the blood of 
men (Analysis 1); to examine the associations between 
testosterone concentrations and subsequent incidence of 
cardiovascular events, cardiovascular deaths and all- cause 
mortality in men (Analysis 2); to examine the associations 
between testosterone concentrations and subsequent 
mortality from (and, if available, diagnoses of) common 
cancers in men (Analysis 3) and to examine the associa-
tions between testosterone concentrations and cognitive 
impairment and incident dementia in men (Analysis 4). 
Analysis 2 will evaluate myocardial infarction, stroke and 
heart failure, deaths due to cardiovascular disease and 
the composite endpoint of MACE comprising non- fatal 
myocardial infarction, non- fatal stroke and deaths due to 
cardiovascular disease. Analysis 3 will evaluate outcomes 
of deaths due to and diagnoses of colorectal cancer, lung 
cancer and prostate cancer.
MEthOds And AnAlysIs
IPD meta- analyses will be conducted to understand the 
associations between testosterone and a range of associ-
ated major health outcomes in men. IPD meta- analyses 
have been selected as the most suitable approach because 
(1) the required AD are not available from each of the 
cohorts in published literature; (2) IPD meta- analyses 
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typically have higher statistical power than AD meta- 
analyses and provide scope for controlling for important 
confounders and risk factors.37 38 Where possible, methods 
will adhere to the guidelines for Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses of IPD 
data (completed checklist is provided in online supple-
mentary material) and the Meta- analysis Of Observa-
tional Studies in Epidemiology.41–43
studies selected for inclusion in IPd meta-analyses
Studies will be identified by two independent reviewers 
from a systematic review using online search tools for 
mainstream published (MEDLINE, EMBASE) and grey 
literature (OpenGrey, Mednar) studies, conducted from 
14 June 2019 to 31 December 2019. Eligible studies 
include prospective cohort studies with plasma or serum 
testosterone concentrations measured using mass spec-
trometry with at least 5 years of follow- up data, with 
incident cardiovascular, cancer, mortality, dementia or 
cognitive events recorded (see online supplementary 
table S1 for an example of search criteria to be used). 
The search strategy selects for articles based on words 
or Medical Subject Headings terms matching the rele-
vant exposure (example steps 1–3), outcomes (example 
steps 4–10) and study type (example steps 14–15), then, 
depending on the search tool, filters down to more 
relevant studies, with exclusions of clinical trials and of 
studies on non- humans (example steps 18–27), with no 
date range restrictions. Ahead of the systematic review, 
nine eligible studies (cohorts) had expressed interest 
to collaborate: three from Australia (Busselton Health 
Study,44 Health In Men Study,45 Men Androgen Inflam-
mation Lifestyle Environment and Stress Study46); two 
from Europe (European Male Ageing Study,47 Osteopo-
rotic Fractures in Men Study, Sweden48) and four from 
the USA (Atherosclerosis Risk in Communities Study,49 
Cardiovascular Health Study,50 The Framingham Heart 
Study,51 Osteoporotic Fractures in Men Study, USA52). 
Investigators from eight of these studies have confirmed 
availability of suitable IPD- level data, provisional on 
approvals from their respective Publication and Steering 
Committees. If it is not possible to obtain IPD- level data 
from selected studies, we will request suitable AD- level 
data.
data provision, merging, harmonisation and storage
The project manager will liaise directly with the nomi-
nated contact person for each cohort study to identify, 
specifically, which variables and set of observations will be 
suitable to request. A data request will then be submitted 
to the data custodian for each study. Requested variables 
will be labelled as either ‘highly desirable’ or ‘only if avail-
able’, in order to prioritise efforts in obtaining the key 
variables for analyses and to acknowledge the differing 
availability of variables among studies. A list of variable 
names, definitions and attributes, including numbers of 
rows and columns in each data file(s) will also be requested 
to be provided separately. Methods for ascertaining 
outcome and comorbidity status will be requested, which 
can be used to indicate the relative quality of diagnostic 
information (eg, International Classification of Diseases 
(ICD)- coded diagnoses from hospital inpatient admis-
sions vs self- report information). File transfer will be 
achieved via encrypted file transfer (or other sufficiently 
secure method).
Once each dataset has been received by the project 
manager, the original file(s) will be saved and date- 
stamped in a secure central repository. All subsequent 
manipulations will be completed using copies of the 
original file, with syntax saved as script files. Variable defi-
nitions will be checked, variables inspected for missing 
values and variable properties and value ranges assessed 
to identify possible outliers. A table of summary statistics 
will be calculated and, where possible, analyses run and 
compared with published values to check for data consis-
tency. The nature of any discrepancies identified from 
these checks will need to be understood, and possibly 
resolved, prior to proceeding with the meta- analyses.42 53 54
Depending on the extent of missing- ness, missing 
data will be suitably imputed.54 55 For each analysis, we 
will conduct multiple imputations using a method that 
approximates as close as possible to the substantive 
model.56 The method will likely vary depending on the 
analysis57 and therefore we will consider adapting either a 
fully conditional specification58 or joint modelling frame-
work59 to each case, as is appropriate. The quality of 
imputations will be quantified by using re- imputed values 
to calculate the posterior predictive p values of relevant 
quantities.60 Results from each of the multiply- imputed 
datasets will be suitably pooled to obtain final estimates, 
SEs and 95% CIs.61
Prior to the merging of datasets, a variable to iden-
tify each source study will be appended as the new first 
column. Variable formats will be checked and corrected 
for consistency and participant identifier codes anony-
mised for uniqueness across all studies. Harmonisation 
will be required for some variables (eg, physical activity, 
alcohol consumption) that are recorded differently by 
the different component studies. Where possible, AD 
datasets will be used to reconstruct IPD- level data (that is, 
partially reconstructed IPD) prior to merging.62–64 Should 
this not be possible, the IPD- level data will be aggregated 
and summary estimates made with and without AD- level 
data as sensitivity analyses. It is also possible that some 
studies might have outcomes available for some analyses, 
but not others; in these cases, we will preferentially use 
IPD- level data when available but also seek to use AD- level 
data from those other studies when available. There is no 
requirement to use IPD- level data from the same studies 
across all analyses.
All IPD- level data will be accessible to only the approved 
staff from a secure on- site facility, from rooms that are 
kept locked when unattended and with remote access not 
permitted. IPD- level data are not to be printed in hard 
copy and will only be presented at aggregate level. Data 
analysed for this study will be retained for 5 years after the 
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Table 1 Variables planned to be included in IPD meta- analysis modelling*
Type Analysis 1 Analysis 2 Analysis 3 Analysis 4











Focal predictor – Androgen concentration† Androgen concentration† Androgen concentration†
  Covariates/IV 
demographic
Age Age Age Age
Education level Education level Education level Education level
Ethnicity Ethnicity Ethnicity Ethnicity
Marital status Marital status Marital status Marital status
Site Site Site Site
  Risk factors and
  comorbidities
Alcohol consumption Alcohol consumption Alcohol consumption Alcohol consumption
  BMI, waist BMI, waist BMI, waist BMI, waist
Physical activity Physical activity Physical activity Physical activity
Smoking status Smoking status Smoking status Smoking status
BP, hypertension BP, hypertension BP, hypertension BP, hypertension
  General health General health General health General health
    Atrial fibrillation     
  Prevalent CVD Prevalent CVD     
  Prevalent cancer‡   Prevalent cancer‡   
  Prevalent dementia     Prevalent dementia
  Baseline cognition       
  COPD COPD     





Creatinine level Creatinine level
Lipid lowering medications Lipid lowering medications
Anxiety Anxiety
Depression Depression
Psychotropic drug use Psychotropic drug use
*Black font: highly desirable; Green font: only if available.
†Androgens: total testosterone, dihydrotestosterone, oestradiol, luteinising hormone, sex hormone binding globulin.
‡Subgroup analyses are also planned. For CVD outcomes: heart failure, myocardial infarction, stroke. For cancer outcomes: colorectal cancer, lung 
cancer, prostate cancer.
BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DV, dependent variable; IV, 
independent variables.
last of all proposed analyses are published and will then 
be destroyed. A post- analysis retention period is required 
to enable publication and possible scrutiny of findings. 
Disposal will be carried out according to best practice.
data items
The full list of generic variables to include in meta- 
analyses is presented in table 1. Analysis 1 will model 
relationships of total testosterone concentrations, as 
measured in serum or plasma samples (dependent vari-
able), with key demographic variables and risk factors 
for disease (predictor variables). Time- to- event variables 
obtained from follow- up data will be analysed in Analysis 
2 and 3 (outcomes), and their associations with testos-
terone concentrations (focal predictor) and other poten-
tial confounders and risk factors (predictor variables). 
Records of dementia diagnoses (physician or other-
wise categorised) and relative cognitive function (for 
example, from test scores) will be analysed in Analysis 4, 
and their associations with testosterone concentrations 
and other potential confounders and risk factors. Anal-
yses of relationships with other sex hormones instead of 
testosterone, including dihydrotestosterone, oestradiol, 
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luteinising hormone (LH) and sex hormone binding 
globulin (SHBG), will be conducted where sufficient data 
are available. For exploratory analyses, free testosterone, 
the amount in the circulation which is not protein- bound, 
will be calculated from measured total testosterone and 
SHBG.65 Covariates were selected to include those used 
in previous studies, as well as those that are typically 
recorded. The full list of proposed variables to include in 
the meta- analyses is presented in table 1.
statistical analysis
Since the datasets to be analysed are sampled from 
different populations, a random- effects meta- analysis 
is appropriate, as it acknowledges that effects will vary 
among studies due to differences in local factors.66 One- 
stage IPD meta- analyses will be performed. Each IPD 
meta- analysis will involve fitting a model with study esti-
mated as either a fixed or random term, to account for 
related observations within studies, and testosterone 
modelled as random slopes (when modelled as a contin-
uous predictor) or intercepts (when modelled as a cate-
gorical predictor), to harmonised, merged data from all 
cohorts. The underlying statistical model and estimates of 
effect size will be specific to each of the proposed analyses 
and are outlined as follows.
Analysis 1: factors associated with testosterone concentrations in 
men and characterisation of reference ranges
Linear mixed models (LMMs) or generalised linear 
mixed models (GLMMs) will be used to model the rela-
tion between the predictors (independent variables) and 
each hormonal variable (testosterone, dihydrotestos-
terone, oestradiol, LH and SHBG) as five separate IPD 
meta- analyses. Suspected non- linear relationships, at 
the scale of the linear predictor, will be investigated and 
modelled appropriately (eg, splines with pre- set knot loca-
tions and linear boundary constraints). Measures of effect 
size may include (but are not limited to): η2,67 68 Pear-
son’s r, standardised mean difference to the reference 
level (categorical predictors) and standardised difference 
for an increase in one SD (continuous predictors). In the 
case of non- linear relations, we will graphically describe 
the relationship with comparisons made with appropriate 
reference points. Reference ranges will be derived based 
on the distributions of testosterone in healthy men.
Analysis 2: associations between testosterone concentrations and 
subsequent incidence of cardiovascular events, cardiovascular 
deaths and all-cause mortality
Cox proportional hazards models will be used to assess 
the effect of testosterone level on the incident risk of each 
outcome, with separate IPD meta- analyses conducted 
for each outcome (myocardial infarction, stroke, heart 
failure, deaths due to cardiovascular disease and MACE) 
and each hormonal variable (testosterone, dihydrotes-
tosterone, oestradiol, LH and SHBG). Component study 
will be modelled either as a stratified variable39 or as a 
random term, and testosterone as a random term, using 
frailty models, which are a class of survival models that 
incorporate random effects.69–71 Participants with preva-
lent cardiovascular disease at baseline will be excluded. 
The length of follow- up will also be standardised among 
studies in order to maximise data from all datasets, while 
minimising the prospect for variable lengths- to- follow- up 
among studies introducing additional heterogeneity into 
results.55
Multivariable versions of each of these models will 
also be fitted, with additional predictors for poten-
tial confounders and risk factors included (table 1). 
Non- linear associations for continuous variables will be 
modelled using natural splines with pre- specified knots 
and linear boundary constraints. The (standardised) 
measure of effect size used will be the HR. Subgroup anal-
yses will be conducted separately for each of three specific 
types of cardiovascular disease (outcomes): myocardial 
infarction, stroke and heart failure.
Analysis 3: association between testosterone level and subsequent 
incidence of cancer
Cox proportional hazards models will be used to assess 
the effect of testosterone concentrations on the incident 
risk of cancer deaths and, if available, of cancer diag-
noses. IPD meta- analyses will be conducted separately 
for each of these outcomes and for each hormonal vari-
able as focal predictor (testosterone, dihydrotestoterone, 
oestradiol, LH and SHBG). Component study will be 
modelled either as a stratified variable39 or as a random 
term, and testosterone as a random term, using frailty 
models.69–71 Participants with prevalent cancer diagnosis 
at baseline will be excluded. The length of follow- up will 
be standardised among studies in order to maximise data 
from all datasets, while minimising the prospect for vari-
able lengths- to- follow- up among studies introducing addi-
tional heterogeneity into results.55
Multivariable versions of each of these models will 
also be fitted, with additional predictors for poten-
tial confounders and risk factors included (table 1). 
Non- linear associations for continuous variables will be 
modelled using natural splines with pre- specified knots 
and linear boundary constraints. The (standardised) 
measure of effect size used will be the HR. Subgroup 
analyses will be conducted separately for each of three 
common types of cancers in men (outcomes): colorectal 
cancer, lung cancer and prostate cancer. For these anal-
yses, men with the relevant cancer type at baseline will be 
excluded from that specific analysis. Thus men with prev-
alent colorectal cancer (but not other cancer types) will 
be excluded in the analysis of incident colorectal cancer; 
similarly for the analyses of incident lung and prostate 
cancer, men with lung or prostate cancer at baseline will 
be excluded.
Analysis 4: associations of testosterone levels with cognitive 
impairment and incident dementia in men
LMMs and GLMMs will be used to model the association 
of testosterone concentrations with cognitive impair-
ment (cross- sectional analyses of baseline data). Cox 
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proportional hazards models will be used to assess the 
effect of testosterone concentrations on the incident 
risk of dementia. Men with prevalent dementia will be 
excluded from this analysis. We will also ask for follow- up 
cognition test scores, and if available, will run an analysis 
of changes in cognition test scores from baseline as an 
outcome. Separate IPD meta- analyses will be conducted 
for each hormonal variable as a focal predictor (testos-
terone, dihydrotestosterone, oestradiol, LH and SHBG). 
Component study will be modelled as a fixed or random 
intercept term in LMMs and GLMMs and as a strati-
fied factor or frailty model random term in Cox regres-
sions. Multivariable versions of each of these models 
will also be fitted, with additional predictors for poten-
tial confounders and risk factors included (table 1). 
Suspected non- linear relationships, at the scale of the 
linear predictor, will be investigated and modelled using 
splines with pre- specified knots and linear boundary 
constraints. Measures of effect size may include: η2, Pear-
son’s r, standardised mean difference to the reference 
level (categorical predictors), standardised difference for 
an increase in one SD (continuous predictors), OR for 
LMMs and GLMMs and HR for Cox regressions.
Throughout all analyses, contour- enhanced funnel plots 
will be constructed to visually assess patterns in estimates 
of effect sizes and precision among studies, to investigate 
heterogeneity and possible meta- biases.72–74 The relative 
amount of heterogeneity will be estimated (eg, using I2) 
and forest plots presented. Subgroup or meta- regression 
analyses may be conducted if pronounced heterogeneity 
is estimated.66
Patient and public involvement
This IPD meta- analysis will use existing secondary data. 
Patients and public were not involved in the design, 
recruitment or conduct of this IPD meta- analysis. The 
results of this study will be shared with the primary inves-
tigators of the shared studies and disseminated as publi-
cations in open- access journals.
EthICs And dIssEMInAtIOn
Ethics approvals obtained for each of the participating 
cohorts state that participants have consented to have 
their data collected and used for research purposes. 
Furthermore, there are no expected harms or risks to 
participants, as data have already been collected within 
each individual cohort, under existing ethics approvals. 
De- identified data will be collated and analysed, with no 
new procedures planned for participants. The AIMS has 
been assessed as exempt from ethics review by the Human 
Research Ethics Office at the University of Western 
Australia (file reference number RA/4/20/5014). 
Research findings will be disseminated to the scientific 
and broader community via the publication of the four 
planned research articles, at scientific conferences and 
meetings of relevant professional societies (including 
the Endocrine Society) to ensure the clinical translation 
and uptake of findings. Collaborating cohort studies each 
have their own individual policies and strategies in place 
for the dissemination of findings to study participants and 
local communities.
dIsCussIOn
Although several published meta- analyses have investi-
gated associations of endogenous testosterone with health 
outcomes in men,75–86 none have conducted IPD meta- 
analyses of health outcomes as planned for this study. A 
previous IPD meta- analysis focussed on the outcome of 
metabolic syndrome.78 Results from this study will improve 
on previously published estimates from individual studies, 
in terms of the generalisability of findings. Estimates from 
the IPD meta- analyses are also likely to be more reliable 
than those published from conventional meta- analyses 
because they typically have higher statistical power and 
provide scope for controlling for important confounders 
and risk factors.37 38 Uncertainty will undoubtedly remain 
due to the possibility of confounding influences of unad-
justed effects. However, unlike a randomised controlled 
trial, this study avoids the need to subject individuals to 
interventions, and provides more comprehensive char-
acterisation of temporal relationships between baseline 
testosterone concentrations and a range of key health 
outcomes.87
Accordingly, it is hoped that the AIMS collaboration will 
ultimately complement the research efforts and outputs 
from multiple prospective cohort studies by drawing on 
the collective body of evidence to clarify the role of endog-
enous sex hormone levels on major health outcomes in 
men. It is possible that this work might also elucidate new 
understanding, arising from improved scope for fitting 
more complex models due to increased statistical power 
or from patterns detected in subgroup or meta- regression 
analyses. Clinically, research outputs will be used to iden-
tify the scope and optimal recruitment criteria for future 
trials of testosterone therapy. These data will also allow 
reference ranges for testosterone in men across ages and 
geographical locations to be refined, to inform recom-
mendations for clinical practice more generally.
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